



GB-88

PAS編号 RC10061 CAS編号 1416435-96-5 分子式 C32H42N4O4 分子量 546.70 作用靶点 Protease Activated Receptor (PAR) 作用通路 GPCR/G Protein 储存 Powder: -20°C for 3 years In solvent: -80°C for 1 year 溶解性 DMSO: 31.25 mg/mL (57.16 mM),Sonication is recommended. Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible. 描述 GB-88 is an selective , oral non-peptide antagonist of PAR2, inhibits PAR2 activated Ca2+ release with an IC50 of 2 µM. In vitro GB-88 inhibits iCa2+ release induced in HT29 cells by trypsin, 2f-LIGRLO-NH2 and GB110 (PAR2 agonists).?And antagonism by GB-88 is agonist dependent. In vivo GB-88 inhibits PAR2-induced acute inflammation in vivo.GB-88 is both orally active and anti-inflammatory in vivo, with specific antagonist activity against four structurally and mechanistically different PAR2 agonists (2f-LIGRLO-NH2, trypsin, SLIGRL-NH2 and GB110).		
分子式 C32H42N4O4 分子量 546.70 作用靶点 Protease Activated Receptor (PAR) 作用通路 GPCR/G Protein 储存 Powder: -20°C for 3 years In solvent: -80°C for 1 year 溶解性 DMSO: 31.25 mg/mL (57.16 mM), Sonication is recommended. Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible. 描述 GB-88 is an selective , oral non-peptide antagonist of PAR2, inhibits PAR2 activated Ca2+ release with an IC50 of 2 µM. In vitro GB-88 inhibits iCa2+ release induced in HT29 cells by trypsin, 2f-LIGRLO-NH2 and GB110 (PAR2 agonists). PAR2-induced acute inflammation in vivo. GB-88 is both orally active and anti-inflammatory in vivo, with specific antagonist activity against four structurally and mechanistically different PAR2 agonists (2f-LIGRLO-NH2, trypsin, SLIGRL-NH2 and	产品编号	RC10061
分子量 546.70 作用靶点 Protease Activated Receptor (PAR) 作用通路 GPCR/G Protein 储存 Powder: -20°C for 3 years In solvent: -80°C for 1 year 溶解性 DMSO: 31.25 mg/mL (57.16 mM), Sonication is recommended. Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible. 描述 GB-88 is an selective , oral non-peptide antagonist of PAR2, inhibits PAR2 activated Ca2+ release with an IC50 of 2 μM. In vitro GB-88 inhibits iCa2+ release induced in HT29 cells by trypsin, 2f-LIGRLO-NH2 and GB110 (PAR2 agonists).?And antagonism by GB-88 is agonist dependent. In vivo GB-88 inhibits PAR2-induced acute inflammation in vivo.GB-88 is both orally active and anti-inflammatory in vivo, with specific antagonist activity against four structurally and mechanistically different PAR2 agonists (2f-LIGRLO-NH2, trypsin, SLIGRL-NH2 and	CAS编号	1416435-96-5
作用靶点 Protease Activated Receptor (PAR) 作用通路 GPCR/G Protein 储存 Powder: -20°C for 3 years In solvent: -80°C for 1 year 溶解性 DMSO: 31.25 mg/mL (57.16 mM), Sonication is recommended. Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible. 描述 GB-88 is an selective , oral non-peptide antagonist of PAR2, inhibits PAR2 activated Ca2+ release with an IC50 of 2 μM. In vitro GB-88 inhibits iCa2+ release induced in HT29 cells by trypsin, 2f-LIGRLO-NH2 and GB110 (PAR2 agonists).?And antagonism by GB-88 is agonist dependent. In vivo GB-88 inhibits PAR2-induced acute inflammation in vivo.GB-88 is both orally active and anti-inflammatory in vivo, with specific antagonist activity against four structurally and mechanistically different PAR2 agonists (2f-LIGRLO-NH2, trypsin, SLIGRL-NH2 and	分子式	C32H42N4O4
作用範点 Protease Activated Receptor (PAR) 作用通路 GPCR/G Protein GPCR/G Protein GPCR/G Protein GPCR/G Protein Mapping DMSO: 31.25 mg/mL (57.16 mM),Sonication is recommended. Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible. GB-88 is an selective , oral non-peptide antagonist of PAR2, inhibits PAR2 activated Ca2+ release with an IC50 of 2 μM. In vitro GB-88 inhibits iCa2+ release induced in HT29 cells by trypsin, 2f-LIGRLO-NH2 and GB110 (PAR2 agonists). And antagonism by GB-88 is agonist dependent. In vivo GB-88 inhibits PAR2-induced acute inflammation in vivo. GB-88 is both orally active and anti-inflammatory in vivo, with specific antagonist activity against four structurally and mechanistically different PAR2 agonists (2f-LIGRLO-NH2, trypsin, SLIGRL-NH2 and	分子量	
 储存 Powder: -20°C for 3 years In solvent: -80°C for 1 year 溶解性 DMSO: 31.25 mg/mL (57.16 mM),Sonication is recommended. Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible. 描述 GB-88 is an selective , oral non-peptide antagonist of PAR2, inhibits PAR2 activated Ca2+ release with an IC50 of 2 μM. In vitro GB-88 inhibits iCa2+ release induced in HT29 cells by trypsin, 2f-LIGRLO-NH2 and GB110 (PAR2 agonists).?And antagonism by GB-88 is agonist dependent. In vivo GB-88 inhibits PAR2-induced acute inflammation in vivo.GB-88 is both orally active and anti-inflammatory in vivo, with specific antagonist activity against four structurally and mechanistically different PAR2 agonists (2f-LIGRLO-NH2, trypsin, SLIGRL-NH2 and 	作用靶点	N-0 0
溶解性 DMSO: 31.25 mg/mL (57.16 mM),Sonication is recommended. Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible. 描述 GB-88 is an selective, oral non-peptide antagonist of PAR2, inhibits PAR2 activated Ca2+ release with an IC50 of 2 μM. In vitro GB-88 inhibits iCa2+ release induced in HT29 cells by trypsin, 2f-LIGRLO-NH2 and GB110 (PAR2 agonists).?And antagonism by GB-88 is agonist dependent. In vivo GB-88 inhibits PAR2-induced acute inflammation in vivo.GB-88 is both orally active and anti-inflammatory in vivo, with specific antagonist activity against four structurally and mechanistically different PAR2 agonists (2f-LIGRLO-NH2, trypsin, SLIGRL-NH2 and	作用通路	GPCR/G Protein
Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible. 描述 GB-88 is an selective , oral non-peptide antagonist of PAR2, inhibits PAR2 activated Ca2+ release with an IC50 of 2 μM. In vitro GB-88 inhibits iCa2+ release induced in HT29 cells by trypsin, 2f-LIGRLO-NH2 and GB110 (PAR2 agonists).?And antagonism by GB-88 is agonist dependent. In vivo GB-88 inhibits PAR2-induced acute inflammation in vivo.GB-88 is both orally active and anti-inflammatory in vivo, with specific antagonist activity against four structurally and mechanistically different PAR2 agonists (2f-LIGRLO-NH2, trypsin, SLIGRL-NH2 and	储存	Powder: -20°C for 3 years In solvent: -80°C for 1 year
solubility of the product in different solvents. Please use it as soon as possible. 描述 GB-88 is an selective , oral non-peptide antagonist of PAR2, inhibits PAR2 activated Ca2+ release with an IC50 of 2 μM. In vitro GB-88 inhibits iCa2+ release induced in HT29 cells by trypsin, 2f-LIGRLO-NH2 and GB110 (PAR2 agonists).?And antagonism by GB-88 is agonist dependent. In vivo GB-88 inhibits PAR2-induced acute inflammation in vivo.GB-88 is both orally active and anti-inflammatory in vivo, with specific antagonist activity against four structurally and mechanistically different PAR2 agonists (2f-LIGRLO-NH2, trypsin, SLIGRL-NH2 and	溶解性	DMSO: 31.25 mg/mL (57.16 mM),Sonication is recommended.
描述 GB-88 is an selective , oral non-peptide antagonist of PAR2, inhibits PAR2 activated Ca2+ release with an IC50 of 2 μM. In vitro GB-88 inhibits iCa2+ release induced in HT29 cells by trypsin, 2f-LIGRLO-NH2 and GB110 (PAR2 agonists).?And antagonism by GB-88 is agonist dependent. In vivo GB-88 inhibits PAR2-induced acute inflammation in vivo.GB-88 is both orally active and anti-inflammatory in vivo, with specific antagonist activity against four structurally and mechanistically different PAR2 agonists (2f-LIGRLO-NH2, trypsin, SLIGRL-NH2 and		Please select the appropriate solvent to prepare the stock solution, according to the
release with an IC50 of 2 μM. In vitro GB-88 inhibits iCa2+ release induced in HT29 cells by trypsin, 2f-LIGRLO-NH2 and GB110 (PAR2 agonists).?And antagonism by GB-88 is agonist dependent. In vivo GB-88 inhibits PAR2-induced acute inflammation in vivo.GB-88 is both orally active and anti-inflammatory in vivo, with specific antagonist activity against four structurally and mechanistically different PAR2 agonists (2f-LIGRLO-NH2, trypsin, SLIGRL-NH2 and		solubility of the product in different solvents. Please use it as soon as possible.
In vitro GB-88 inhibits iCa2+ release induced in HT29 cells by trypsin, 2f-LIGRLO-NH2 and GB110 (PAR2 agonists).?And antagonism by GB-88 is agonist dependent. In vivo GB-88 inhibits PAR2-induced acute inflammation in vivo.GB-88 is both orally active and anti-inflammatory in vivo, with specific antagonist activity against four structurally and mechanistically different PAR2 agonists (2f-LIGRLO-NH2, trypsin, SLIGRL-NH2 and	描述	GB-88 is an selective , oral non-peptide antagonist of PAR2, inhibits PAR2 activated Ca2+
(PAR2 agonists).?And antagonism by GB-88 is agonist dependent. In vivo GB-88 inhibits PAR2-induced acute inflammation in vivo.GB-88 is both orally active and anti-inflammatory in vivo, with specific antagonist activity against four structurally and mechanistically different PAR2 agonists (2f-LIGRLO-NH2, trypsin, SLIGRL-NH2 and		release with an IC50 of 2 μM.
In vivo GB-88 inhibits PAR2-induced acute inflammation in vivo.GB-88 is both orally active and anti-inflammatory in vivo, with specific antagonist activity against four structurally and mechanistically different PAR2 agonists (2f-LIGRLO-NH2, trypsin, SLIGRL-NH2 and	In vitro	GB-88 inhibits iCa2+ release induced in HT29 cells by trypsin, 2f-LIGRLO-NH2 and GB110
anti-inflammatory in vivo, with specific antagonist activity against four structurally and mechanistically different PAR2 agonists (2f-LIGRLO-NH2, trypsin, SLIGRL-NH2 and		(PAR2 agonists).?And antagonism by GB-88 is agonist dependent.
mechanistically different PAR2 agonists (2f-LIGRLO-NH2, trypsin, SLIGRL-NH2 and	In vivo	GB-88 inhibits PAR2-induced acute inflammation in vivo.GB-88 is both orally active and
		anti-inflammatory in vivo, with specific antagonist activity against four structurally and
GB110).		mechanistically different PAR2 agonists (2f-LIGRLO-NH2, trypsin, SLIGRL-NH2 and
		GB110).

RV:2.0-2021

